πŸ‡ΊπŸ‡Έ FDA
Patent

US 9926602

Recurrent gene fusions in prostate cancer

granted A61PA61P13/08A61P35/00

Quick answer

US patent 9926602 (Recurrent gene fusions in prostate cancer) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue Mar 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61P, A61P13/08, A61P35/00